Please use this identifier to cite or link to this item: http://elea.unisa.it/xmlui/handle/10556/639
Title: To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator
Authors: Sorriento, Daniela
Illario, Maddalena
Finelli, Rosa
Iaccarino, Guido
Keywords: Transcription factors;IkB;GRK5;Cancer
Issue Date: 2012
Citation: Sorriento D, Illario M, Finelli R, Iaccarino G. To NFkB or not to NFkB: the dilemma on how to inhibit a cancer cell fate regulator. Translational Medicine @ UniSa 2012;4(9):73-85
Abstract: Nuclear factor B (NFB) is a transcription factor that plays an important role in carcinogenesis as well as in the regulation of inflammatory response. NFB is constitutively expressed in tumours where it induces the expression of genes which promote cell proliferation, apoptotic events, angiogenesis, invasion and metastasis. Furthermore, many cancer cells show aberrant or constitutive NFB activation that mediates resistance to chemo- and radio-therapy. Therefore, the inhibition of NFB activity appears a potential therapeutic strategy for cancer treatment. In this review, we focus on the role of NFB in carcinogenesis and summarize actual inhibitors of NFB that could be potential therapeutic target in cancer therapy.
URI: http://hdl.handle.net/10556/639
ISSN: 2239-9747
Appears in Collections:Translational Medicine @ UniSa. Vol.4 (sept.-dec. 2012)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.